about
Targeting FcRn for the modulation of antibody dynamicsBeyond new chemical entities: advancing drug development based on functional versatility of antibodiesThe effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo.Importance of avidity for an endogenous drug carrier: an antibody carrier for CpG oligonucleotides.A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis.
P2860
Q28080589-3A17EDA4-A518-466D-8FCC-23F20008B561Q30386064-045D5B94-C675-4F42-9CC9-AF62933B86ECQ30566003-3C5F739A-115D-4256-93CD-1C1D81CB7A17Q35990439-A51FEBBF-76D7-4904-97F2-38582FBA6734Q39683433-A1756B57-8F5A-40F8-AD8E-2322678DAA3EQ49805666-71438539-FF5E-4185-906C-7790815A9614Q52589113-D7DD5EEF-864B-4142-B39C-20432D24FE5B
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Antibody buffering of a ligand in vivo
@ast
Antibody buffering of a ligand in vivo
@en
type
label
Antibody buffering of a ligand in vivo
@ast
Antibody buffering of a ligand in vivo
@en
prefLabel
Antibody buffering of a ligand in vivo
@ast
Antibody buffering of a ligand in vivo
@en
P2860
P356
P1476
Antibody buffering of a ligand in vivo
@en
P2093
Carol E O'Hear
Jefferson Foote
P2860
P356
10.1073/PNAS.0405797102
P407
P577
2004-12-22T00:00:00Z